Omeros Corporation Overview
Industry: Biotechnology
Sector: Healthcare
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical progra Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Stored reported-result values did not pass automated reconciliation.
What changed
- Open the SEC source filing while these values are reprocessed.
Source review
Mavefund has withheld unreconciled figures from the public page.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
FORM 10-Q
May 13, 2026
SEC filing
FORM 8-K
May 13, 2026
Earnings release
EXHIBIT 99.1
Mar 31, 2026
SEC filing
FORM 10-K
Mar 31, 2026
SEC filing
FORM 8-K
Mar 31, 2026
SEC filing
FORM 8-K
Jan 07, 2026
SEC filing
FORM 8-K
Nov 13, 2025
SEC filing
FORM 10-Q
Nov 13, 2025
Earnings release
EXHIBIT 99.1
Nov 13, 2025
SEC filing
FORM 10-Q
Aug 14, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
OMER Aug 2026 5.000 call (OMER260821C00005000) interactive stock chart
Headline from Yahoo Finance UK: OMER Aug 2026 5.000 call (OMER260821C00005000) interactive stock chart.
Form 4 Omeros Corporation For: 24 July By Investing.com
Headline from Investing.com Nigeria: Form 4 Omeros Corporation For: 24 July By Investing.com.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Headline from PR Newswire: INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER.
Emplifi Appoints Omer Sharon as Chief Product & Technology Officer to Advance its Autonomous Customer Experience Platform
Headline from PR Newswire: Emplifi Appoints Omer Sharon as Chief Product & Technology Officer to Advance its Autonomous Customer Experience Platform.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Headline from PR Newswire: INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER.
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return
Headline from Yahoo Finance: Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.